Webster Financial Corporation has announced the pricing of the underwritten secondary offering by Warburg Pincus Private Equity X, L.P. and one of its affiliates of 8,744,850 shares of Webster common stock. All of the shares are being sold by Warburg Pincus and the firm will receive all of the net proceeds from the offering.
You are browsing the archive for Warburg Pincus - peHUB.
Warburg Pincus may be having problems selling Bausch & Lomb, but that hasn’t stopped the global PE firm from getting some of its investment back.
Eye care company Bausch & Lomb Holdings, owned by private equity firm Warburg Pincus, filed with U.S. regulators to raise up to $100 million in an initial public offering, writes Reuters. The proposed IPO could raise as much as $1.5 billion and is expected to value Bausch & Lomb at about $9 billion to $10 billion, Reuters reported earlier in March.
Cinven and Warburg Pincus are planning to further reduce their stake in Ziggo. They intend to sell around 40 million ordinary shares in Ziggo N.V. via an accelerated bookbuild resulting in a stake of approximately 17.1 percent in the Dutch provider of entertainment, information and communication.
Warburg Pincus has agreed to sell 2,500,000 shares of Primerica‘s common stock in an underwritten public offering. Closing of the offering is expected to occur on February 15, 2013, subject to customary closing conditions. Citigroup is acting as book-running manager for the offering.
Warburg Pincus has appointed Janet Vergis as an Executive-in-Residence. Vergis will support the firm in the identification and evaluation of investment opportunities in the biopharmaceutical sector, particularly in the United States.
Warburg Pincus has acquired JHP Pharmaceuticals for $195 million. The seller is Morgan Stanley Principal Investments. JHP’s current management team will continue to hold an interest. Parsippany, N.J.-based JHP specializes in sterile injectable products. Morgan Stanley & Co. advised JHP.